Recon: 23andMe Gets $300M Boost From GlaxoSmithKline

• Senate panel approves bill banning 'gag clauses' in pharmacy contracts (The Hill) (STAT-$)
• 23andMe Gets $300 Million Boost From GlaxoSmithKline To Develop New Drugs (Forbes) (WSJ) (CNBC) (Fierce) (Reuters) (Bloomberg) (Endpoints)
• In pursuit of Alzheimer's, cancer, growing Alector lands $133 million (San Francisco Business Times-$) (Fierce) (Business Insider) (MedCity News) (Forbes)
• ResTORbio Shares Soar on Clinical Data From Lung Infection Drug (Xconomy) (Endpoints) (Fierce)
• Keytruda extends survival in first-line head and neck cancer trial (PharmaTimes) (Endpoints)
• Indivior shares tumble 20% on profit and market share uncertainty (Financial Times) (Reuters)
• NIH teams with Google Cloud for new biomedical research project (Healthcare Dive) (Business Standard) (GenomeWeb)
• Pfizer to build new facility, add 450 jobs in Michigan (AP News) (Detroit Free Press) (Fierce)

• Top EU court: GMO rules cover plant gene editing technique (Reuters) (The Guardian)
• Vaccine scandals taint Beijing's ambition to become a global pharmaceutical powerhouse (CNBC)
• Hong Kong clinics prepare for influx of mainland visitors after China vaccine scandal (Reuters)
• Multi-disease health fairs, universal “test and treat” help East African communities achieve HIV benchmarks (NIH)
• The HPRA is pleased to announce that we are transitioning to a new human medicines electronic workflow system (HPRA)

• Gilead's Truvada for PrEP can reduce HIV rates, but activists decry unequal access (Fierce) (AP News) (MedPage Today)
• Déjà Voodoo: Pharma’s Promises To Curb Drug Prices Have Been Heard Before (KHN)
• RxLegal: A Rapid Review of Right-To-Try. (PubMed)
• Scientist Invented A New Pathway To Approve Biosimilars - And The FDA Is Listening (Forbes)
• AbbVie prices new endometriosis drug at $10,000 a year (Reuters)
• U.S. to narrow opioid bribe case against Insys founder, others (Reuters)
• Paying for therapies that cure: innovative solutions needed (STAT)
• Prescription apps are gaining ground — and drug makers’ backing — as digital therapeutics (STAT-$)
• Activists want the NIH to break patents on a Gilead drug for preventing HIV (STAT-$)
• Illinois Law Expands Ban on Discharging Unused Medicines (Bloomberg-$)
• Shareholder Accuses Acadia of Hiding Nuplazid Safety Issues (Bloomberg-$)
• Zavante CEO sells his late-stage antibiotic biotech to Nabriva — grabbing the helm in the deal (Endpoints)
• bluebird bio to raise $550 million through public offering (The Pharma Letter)
• Valsartan products not recalled as of July 24, 2018 (FDA)
• Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Permanent Discontinuation or Interruption in Manufacturing of Certain Drug and Biological ProductS (FDA)

• Two Drugs as Good as Three for Treating HIV (Labiotech) (PharmaTimes) (Pharmabiz)
• Can gene therapy halt diseases in babies before they’re even born? (STAT)
• Takeda R&D team rings the blockbuster bell with key PhIII success in frontline lung cancer (Endpoints)
• Janssen Presents Switch Data for New HIV-1 Treatment SYMTUZA (D/C/F/TAF) and Second Study Supporting its Use in a Rapid Initiation Scenario (Press)
• First Long-term Immune Response Data for Investigational HIV-1 Preventive Vaccine Announced by Johnson & Johnson (Press)
• Corium Presents Additional Positive Clinical Results at Alzheimer's Association International Conference 2018 (Press)
• Eisai and Biogen Present Detailed Results From Phase II Clinical Study of Elenbecestat in MCI and Mild to Moderate Alzheimer’s Disease at Alzheimer’s Association International Conference (AAIC) 2018 (Press)

• Stryker Beats Earnings Estimates, Barely Beats Revenue Estimates (Forbes)
• Nevro shares plunge, rebound on court ruling in Boston Scientific spa (MassDevice)
• Boston Scientific beats 2Q earnings expectations (Minneapolis Star Tribune)
• Healthy.io gets FDA nod for smartphone camera-based home urine test (MobiHealthNews)
• Bayer Essure Suits Skyrocketed as FDA Pushed Stronger Warnings (Bloomberg-$)
• 3-D Color X-Rays Could Help Spot Deadly Disease Without Surgery (NYT)
• The Bleeding Edge: Netflix medical devices documentary is terrifying (The Guardian)
• Houston medical device startup hires former Abbott exec as CEO (Houston Business Journal-$)
• UMB-born medical device startup raises $2.35 million, moves toward FDA clearance (Baltimore Business Journal-$)
• Siemens Healthineers Transforms Care Delivery with Innovative New Tests for Diagnosing Heart Attacks Faster (Press)
• Abbott Introduces Breakthrough Point-of-Care Test, the m-PIMA HIV-1/2 Viral Load (VL), at AIDS 2018 Amsterdam (Press)
• First ischemic stroke patients treated with EMBOTRAP II revascularization device since commercial availability in US (Press)

• Ex-Apple Health director is now working to fix medical records (CNBC)
• Medical Records’ Dirty Data Hinder AI’s Role in Research (Bloomberg-$)
• Blockchains for biomedicine and health care are coming. Buyer: be informed (STAT)
• Democrats take aim at high drug prices with bill allowing Medicare to negotiate (STAT-$)
• Fauci: HIV remission free of antiretroviral therapy is a feasible goal (NIH)
• Anthem's Focus On Medicare Over Obamacare Boosts Profits (Forbes)
• Centene Won't Gobble Doctors Like Other Insurers (Forbes)

• FDA Advisory Committee Calendar

• UK Aid raises the voices of grassroots HIV organisations (Gov UK)
• IT systems unavailable from 27 to 30 July 2018: EMA website and online applications will be temporarily unavailable (EMA)
• Fertility treatment doesn't boost overall risk of breast, ovary or uterus cancers (Reuters)
• Opioid analgesics, Z-drugs linked to harmful effects in dementia patients (PharmaTimes)
• Biosimilar switches and healthcare gains (pharmaphorum)
• Rhythm Pharma gets European PRIME designation for setmelanotide in rare genetic disorders of obesity (Pharmabiz)
• Janssen mulls legal proceedings against Russia’s Pharmsyntez (The Pharma Letter-$)
• Omeros’ OMS721 Receives European Orphan Drug Designation Positive Opinion for Treatment in Hematopoietic Stem Cell Transplantation (Press)

• Vaccine scandal: Chinese pharma firm chairman arrested (Business Standard)
• ADHD tied to increased concussion risk for kids (Reuters)
• Government agrees to raise Lipiodol price (Korea Biomedical Review)
• Luye wins China approval for Seroquel XR (The Pharma Letter)

• Even after 10 months, Maharashtra govt still waiting for lab survey report to initiate action against illegal labs (Pharmabiz)

• Police can access My Health Record without court order, parliamentary library warns (The Guardian)
• 'False and reckless': Health Minister slams anti-vaccination documentary maker (The Sydney Morning Herald)

• N.B. gov't may launch lawsuit over opioid crisis (The Canadian Press)
• Baxter Announces Health Canada Approval of Spectrum IQ Infusion System (Press)

• Study: Lowering blood pressure helps prevent mental decline (AP News)
• IBM’s Watson supercomputer recommended ‘unsafe and incorrect’ cancer treatments, internal documents show (STAT-$)
• Mobile App Will Transform Data Entry And Collection In Clinical Studies, Company Says (Forbes)
• Want to reach smartphone-happy doctors? Hint: Typical mobile marketing won't work (Fierce)
• The Next Cancer Drug Might Start in Outer Space (Bloomberg-$)